SEC Company Response from Oncocyte Corp (OCX) (CIK 0001642380) (IMDX) — Oct 12, 2017

Oncocyte Corp (OCX) (CIK 0001642380)
Date: Oct. 12, 2017 · CIK: 0001642380 · Accession: 0001493152-17-011540

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-220769

Date

Oct. 12, 2017

Author

President and Chief

Form

CORRESP

Company

Oncocyte Corp (OCX) (CIK 0001642380)

Letter

Re: OncoCyte Corporation

October 12, 2017

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, NE

Washington, DC 20549-4561

Attn: Irene Paik

Registration Statement on Form S-3

File No. 333-220769

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, OncoCyte Corporation hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Time, on Monday, October 16, 2017, or as soon thereafter as practicable.

Thank you for your assistance. Should you have any questions, please contact Andrew Ledbetter of DLA Piper LLP (US) at (206) 839-4845, or his colleague Kevin Criddle at (206) 839-4857.

Very
truly yours,
OncoCyte
Corporation

Show Raw Text

CORRESP
1
filename1.htm

October
12, 2017

Via
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, NE

Washington,
DC 20549-4561

    Attn:
    Irene
    Paik

    Re:
    OncoCyte
    Corporation

    Registration
    Statement on Form S-3

    File
    No. 333-220769

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the Securities Act of 1933, as amended, OncoCyte Corporation hereby requests that the Securities and Exchange Commission
accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Time, on Monday, October 16,
2017, or as soon thereafter as practicable.

Thank
you for your assistance. Should you have any questions, please contact Andrew Ledbetter of DLA Piper LLP (US) at (206) 839-4845,
or his colleague Kevin Criddle at (206) 839-4857.

Very
truly yours,

OncoCyte
Corporation

    /s/
    William Annett

    William Annett

    President and Chief
    Executive Officer

SecProbe.io